SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SLS on Nasdaq
Shares outstanding
105,841,018
Price per share
$3.77
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
32,917,301
Total reported value
$53,012,951
% of total 13F portfolios
0%
Share change
+6,137,446
Value change
+$9,796,867
Number of holders
92
Price from insider filings
$3.77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 6.7% $9,439,667 6,694,799 The Vanguard Group 30 Jun 2025
Anson Funds Management LP 5.7% +16% $9,713,030 +$1,299,254 6,032,938 +15% Anson Funds Management LP 30 Sep 2025
BlackRock, Inc. 5.4% $9,155,886 5,686,886 BlackRock, Inc. 30 Sep 2025

As of 30 Sep 2025, 92 institutional investors reported holding 32,917,301 shares of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS). This represents 31% of the company’s total 105,841,018 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) together control 30% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 6.5% 6,839,905 +2.8% 0% $11,012,247
Anson Funds Management LP 5.7% 6,032,938 +2094% 1.1% $9,713,030
BlackRock, Inc. 5.4% 5,686,886 +24% 0% $9,155,886
MARSHALL WACE, LLP 2.2% 2,357,999 -13% 0% $3,796,377
GEODE CAPITAL MANAGEMENT, LLC 2.1% 2,264,384 +2.9% 0% $3,646,330
STATE STREET CORP 1.3% 1,360,914 +22% 0% $2,191,072
MORGAN STANLEY 1% 1,054,791 -2.7% 0% $1,698,214
Nuveen, LLC 0.94% 997,910 +2.7% 0% $1,606,635
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.82% 863,575 -42% 0% $1,390,356
NORTHERN TRUST CORP 0.69% 731,175 +4.7% 0% $1,177,191
GSA CAPITAL PARTNERS LLP 0.49% 518,995 +22% 0.07% $836,000
Everhart Financial Group, Inc. 0.31% 331,150 0.05% $533,152
MILLENNIUM MANAGEMENT LLC 0.3% 314,702 -72% 0% $506,670
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.28% 294,106 0% 0% $473,511
RENAISSANCE TECHNOLOGIES LLC 0.28% 291,822 0% $469,833
Opus Capital Group, LLC 0.24% 250,000 +4.2% 0.05% $403,000
Bank of New York Mellon Corp 0.19% 205,682 +2.1% 0% $331,147
CITADEL ADVISORS LLC 0.18% 194,357 +129% 0% $312,915
BARCLAYS PLC 0.17% 182,680 +5.7% 0% $294,115
TWO SIGMA INVESTMENTS, LP 0.14% 145,856 -26% 0% $234,828
RHUMBLINE ADVISERS 0.13% 136,639 +0.63% 0% $219,982
DEUTSCHE BANK AG\ 0.11% 121,025 +5083% 0% $194,850
Mariner, LLC 0.1% 108,806 +113% 0% $175,178
JANE STREET GROUP, LLC 0.1% 102,959 +121% 0% $165,764
UBS Group AG 0.08% 84,989 -73% 0% $136,832

Institutional Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,080,578 $4,073,362 +$2,735,542 $3.77 4
2025 Q3 32,917,301 $53,012,951 +$9,796,867 $1.61 92
2025 Q2 26,771,579 $58,629,839 +$27,498,013 $2.19 78
2025 Q1 14,287,843 $15,431,614 +$8,743,249 $1.08 43
2024 Q4 6,195,241 $6,444,304 +$751,052 $1.04 29
2024 Q3 5,385,570 $6,729,539 +$1,661,403 $1.25 33
2024 Q2 4,056,846 $4,828,846 -$3,466,320 $1.19 33
2024 Q1 7,717,105 $7,794,727 +$4,297,256 $1.01 29
2023 Q4 3,408,377 $3,612,756 +$285,784 $1.06 27
2023 Q3 2,751,676 $4,512,830 -$594,240 $1.64 26
2023 Q2 3,093,394 $4,856,468 +$175,524 $1.57 21
2023 Q1 2,975,295 $4,255,203 +$1,438,719 $1.43 21
2022 Q4 1,889,269 $4,456,259 +$93,296 $2.36 28
2022 Q3 2,184,628 $4,411,000 -$489,090 $2.02 23
2022 Q2 2,979,307 $6,641,000 +$1,670,712 $2.23 23
2022 Q1 1,656,864 $11,065,000 -$276,577 $6.68 21
2021 Q4 1,726,932 $9,548,000 -$1,351,972 $5.53 24
2021 Q3 1,859,470 $17,100,000 -$844,204 $9.16 29
2021 Q2 1,897,926 $21,282,000 +$3,093,807 $11.10 28
2021 Q1 1,551,884 $13,239,990 +$5,291,338 $8.54 27
2020 Q4 925,075 $5,374,000 +$2,503,569 $5.81 19
2020 Q3 616,674 $1,633,000 +$397,182 $2.65 10
2020 Q2 455,904 $1,335,000 +$144,562 $2.93 12
2020 Q1 415,637 $720,000 -$87,848 $1.74 10
2019 Q4 388,842 $1,671,000 +$1,671,000 $4.30 9